Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen

about

Atazanavir: its role in HIV treatment Clinical pharmacology, efficacy and safety of atazanavir: a review.Electrocardiogram abnormalities with atazanavir and lopinavir/ritonavir.

P2860

Q37249418-A97A3344-19C0-4996-A0D0-3507D0EB43FC Q37622972-576FA1F7-B9C4-4120-83C8-3E190ECDB08C Q43244207-7DBBCADE-4D91-4A30-8284-105A1AA93DA0

P2860

Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen

Item

http://www.wikidata.org/entity/Q36702983

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Decrease of atazanavir and lop ...... ease inhibitor salvage regimen

@ast

Decrease of atazanavir and lop ...... ease inhibitor salvage regimen

@en

type

Item

label

Decrease of atazanavir and lop ...... ease inhibitor salvage regimen

@ast

Decrease of atazanavir and lop ...... ease inhibitor salvage regimen

@en

prefLabel

Decrease of atazanavir and lop ...... ease inhibitor salvage regimen

@ast

Decrease of atazanavir and lop ...... ease inhibitor salvage regimen

@en

P1476

Decrease of atazanavir and lop ...... ease inhibitor salvage regimen

@en

P2093

Christoph Stephan

http://www.w3.org/2001/XMLSchema#string

Errol Babacan

http://www.w3.org/2001/XMLSchema#string

Nils von Hentig

http://www.w3.org/2001/XMLSchema#string

Pavel Kaykhin

http://www.w3.org/2001/XMLSchema#string

Schlomo Staszewski

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen

Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1

Practical perspectives on the use of tipranavir in combination with other medications: lessons learned from pharmacokinetic studies.

Lopinavir/ritonavir: appraisal of its use in HIV therapy.

Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir.

Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers.

Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen.

Update of the drug resistance mutations in HIV-1: Fall 2005.

Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients.

Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.

P304

2273-2275

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01565-07

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-04-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18411323

http://www.w3.org/2001/XMLSchema#string

P932

2415773

http://www.w3.org/2001/XMLSchema#string

Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen

about

P2860

P2860

Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932